diphosphoric acid has been researched along with Vascular Calcification in 33 studies
diphosphoric acid : An acyclic phosphorus acid anhydride obtained by condensation of two molecules of phosphoric acid.
Vascular Calcification: Deposition of calcium into the blood vessel structures. Excessive calcification of the vessels are associated with ATHEROSCLEROTIC PLAQUES formation particularly after MYOCARDIAL INFARCTION (see MONCKEBERG MEDIAL CALCIFIC SCLEROSIS) and chronic kidney diseases which in turn increase VASCULAR STIFFNESS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, over the last few years, a novel role for ATP as a potent extracellular signaling molecule and the principal source of extracellular pyrophosphate, the main endogenous inhibitor of vascular calcification, has emerged." | 9.41 | Role of the extracellular ATP/pyrophosphate metabolism cycle in vascular calcification. ( Villa-Bellosta, R, 2023) |
| " These hereditary disorders, caused by mutations in genes encoding ATP binding cassette subfamily C member 6, ectonucleotide pyrophosphatase/phosphodiesterase 1, CD73, progressive ankylosis protein, and lamin A/C proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiologic inhibitor of calcium hydroxyapatite deposition in soft connective tissues." | 9.22 | Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification. ( Li, Q; Ralph, D; Uitto, J; van de Wetering, K, 2022) |
| "5mg/kg, intraperitoneal) inhibited the vascular calcification in rats with hypercholesterolemia accompanied by the increase in the level of extracellular inorganic pyrophosphate (PPi), the endogenous inhibitor of vascular calcification." | 7.81 | Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. ( Chan, E; Dai, C; Lu, M; Mei, M; Song, Q; Tang, F; Wang, H; Zhang, S; Zhang, X, 2015) |
| "Plasma levels of pyrophosphate, an endogenous inhibitor of vascular calcification, are reduced in end-stage renal disease and correlate inversely with arterial calcification." | 7.80 | Vascular calcification is dependent on plasma levels of pyrophosphate. ( Lomashvili, KA; Millán, JL; Narisawa, S; O'Neill, WC, 2014) |
| "Excessive vascular calcification in Lmna(G609G) mice is caused by reduced extracellular accumulation of pyrophosphate that results from increased tissue-nonspecific alkaline phosphatase activity and diminished ATP availability caused by mitochondrial dysfunction in vascular smooth muscle cells." | 7.79 | Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. ( Acín-Pérez, R; Andrés, V; Enriquez, JA; López-Otín, C; Osorio, FG; Rivera-Torres, J; Villa-Bellosta, R, 2013) |
| "Pathologic cardiovascular calcification is associated with a number of conditions and is a common complication of chronic kidney disease." | 6.58 | Pyrophosphate deficiency in vascular calcification. ( O'Neill, WC; Villa-Bellosta, R, 2018) |
| " However, over the last few years, a novel role for ATP as a potent extracellular signaling molecule and the principal source of extracellular pyrophosphate, the main endogenous inhibitor of vascular calcification, has emerged." | 5.41 | Role of the extracellular ATP/pyrophosphate metabolism cycle in vascular calcification. ( Villa-Bellosta, R, 2023) |
| " These hereditary disorders, caused by mutations in genes encoding ATP binding cassette subfamily C member 6, ectonucleotide pyrophosphatase/phosphodiesterase 1, CD73, progressive ankylosis protein, and lamin A/C proteins, respectively, are inorganic pyrophosphate (PPi) deficiency syndromes with reduced circulating levels of PPi, the principal physiologic inhibitor of calcium hydroxyapatite deposition in soft connective tissues." | 5.22 | Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification. ( Li, Q; Ralph, D; Uitto, J; van de Wetering, K, 2022) |
| "5mg/kg, intraperitoneal) inhibited the vascular calcification in rats with hypercholesterolemia accompanied by the increase in the level of extracellular inorganic pyrophosphate (PPi), the endogenous inhibitor of vascular calcification." | 3.81 | Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL. ( Chan, E; Dai, C; Lu, M; Mei, M; Song, Q; Tang, F; Wang, H; Zhang, S; Zhang, X, 2015) |
| "Plasma levels of pyrophosphate, an endogenous inhibitor of vascular calcification, are reduced in end-stage renal disease and correlate inversely with arterial calcification." | 3.80 | Vascular calcification is dependent on plasma levels of pyrophosphate. ( Lomashvili, KA; Millán, JL; Narisawa, S; O'Neill, WC, 2014) |
| "Excessive vascular calcification in Lmna(G609G) mice is caused by reduced extracellular accumulation of pyrophosphate that results from increased tissue-nonspecific alkaline phosphatase activity and diminished ATP availability caused by mitochondrial dysfunction in vascular smooth muscle cells." | 3.79 | Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. ( Acín-Pérez, R; Andrés, V; Enriquez, JA; López-Otín, C; Osorio, FG; Rivera-Torres, J; Villa-Bellosta, R, 2013) |
| "Pathologic cardiovascular calcification is associated with a number of conditions and is a common complication of chronic kidney disease." | 2.58 | Pyrophosphate deficiency in vascular calcification. ( O'Neill, WC; Villa-Bellosta, R, 2018) |
| "Pseudoxanthoma elasticum is a prototype of heritable ectopic mineralization disorders, with phenotypic overlap with generalized arterial calcification of infancy and arterial calcification due to CD73 deficiency." | 2.55 | Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016. ( Li, Q; Terry, SF; Uitto, J; van de Wetering, K; Váradi, A, 2017) |
| "CKD and vascular calcification were induced in male Wistar rats by a 0." | 1.43 | Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease? ( Bashir-Dar, R; Behets, GJ; D'Haese, PC; Dams, G; De Maré, A; Marynissen, R; Neven, E; Opdebeeck, B; Riser, BL; Verhulst, A, 2016) |
| "Vascular calcification is a major risk factor of cardiovascular mortality, particularly for patients with end-stage renal disease and diabetes." | 1.38 | Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. ( Dai, XY; Guan, Y; Kong, W; Wang, CY; Wang, X; Wilson, GM; Xu, MJ; Zhao, G; Zhao, MM, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 23 (69.70) | 24.3611 |
| 2020's | 10 (30.30) | 2.80 |
| Authors | Studies |
|---|---|
| Kozák, E | 2 |
| Fülöp, K | 2 |
| Tőkési, N | 2 |
| Rao, N | 1 |
| Li, Q | 8 |
| Terry, SF | 3 |
| Uitto, J | 8 |
| Zhang, X | 2 |
| Becker, C | 1 |
| Váradi, A | 4 |
| Pomozi, V | 3 |
| Villa-Bellosta, R | 8 |
| Ralph, D | 2 |
| van de Wetering, K | 3 |
| Levine, M | 1 |
| Millán, JL | 2 |
| Letavernier, E | 2 |
| Bouderlique, E | 1 |
| Zaworski, J | 2 |
| Martin, L | 2 |
| Daudon, M | 1 |
| Boyce, AM | 1 |
| Gafni, RI | 1 |
| Ferreira, CR | 1 |
| Dedinszki, D | 1 |
| Hegedűs, N | 1 |
| Király, B | 1 |
| Szigeti, K | 1 |
| Ajtay, K | 1 |
| Jakus, Z | 1 |
| Luo, H | 1 |
| Faghankhani, M | 1 |
| Cao, Y | 1 |
| Buchet, R | 1 |
| Tribes, C | 1 |
| Rouaix, V | 1 |
| Doumèche, B | 1 |
| Fiore, M | 1 |
| Wu, Y | 1 |
| Magne, D | 1 |
| Mebarek, S | 1 |
| Shimada, BK | 1 |
| Zoll, J | 1 |
| Kuo, S | 1 |
| Le Saux, O | 1 |
| Hamczyk, MR | 1 |
| Andrés, V | 2 |
| Fuery, MA | 1 |
| Liang, L | 1 |
| Kaplan, FS | 1 |
| Mohler, ER | 1 |
| O'Neill, WC | 3 |
| Khan, T | 1 |
| Sinkevicius, KW | 1 |
| Vong, S | 1 |
| Avakian, A | 1 |
| Leavitt, MC | 1 |
| Malanson, H | 1 |
| Marozsan, A | 1 |
| Askew, KL | 1 |
| Rivera-Torres, J | 1 |
| Osorio, FG | 1 |
| Acín-Pérez, R | 1 |
| Enriquez, JA | 1 |
| López-Otín, C | 1 |
| Leopold, JA | 1 |
| Guo, H | 1 |
| Chou, DW | 1 |
| Berndt, A | 1 |
| Sundberg, JP | 1 |
| Barreto, FC | 1 |
| de Oliveira, RB | 1 |
| Benchitrit, J | 1 |
| Louvet, L | 1 |
| Rezg, R | 1 |
| Poirot, S | 1 |
| Jorgetti, V | 1 |
| Drüeke, TB | 1 |
| Riser, BL | 2 |
| Massy, ZA | 1 |
| Nitschke, Y | 1 |
| Rutsch, F | 1 |
| Lomashvili, KA | 1 |
| Narisawa, S | 1 |
| Shimokado, A | 1 |
| Sun, Y | 1 |
| Nakanishi, M | 1 |
| Sato, F | 1 |
| Oikawa, K | 1 |
| Akasaka, T | 1 |
| Muragaki, Y | 1 |
| Adeva-Andany, MM | 1 |
| Fernández-Fernández, C | 1 |
| Sánchez-Bello, R | 1 |
| Donapetry-García, C | 1 |
| Martínez-Rodríguez, J | 1 |
| Tang, F | 1 |
| Chan, E | 1 |
| Lu, M | 1 |
| Dai, C | 1 |
| Mei, M | 1 |
| Zhang, S | 1 |
| Wang, H | 1 |
| Song, Q | 1 |
| Bristow, SM | 1 |
| Gamble, GD | 1 |
| Pasch, A | 1 |
| Stewart, A | 1 |
| Horne, AM | 1 |
| Reid, IR | 1 |
| Egido, J | 1 |
| Arányi, T | 1 |
| Neven, E | 1 |
| Opdebeeck, B | 1 |
| De Maré, A | 1 |
| Bashir-Dar, R | 1 |
| Dams, G | 1 |
| Marynissen, R | 1 |
| Behets, GJ | 1 |
| Verhulst, A | 1 |
| D'Haese, PC | 1 |
| Sorribas, V | 1 |
| Zhao, G | 1 |
| Xu, MJ | 1 |
| Zhao, MM | 1 |
| Dai, XY | 1 |
| Kong, W | 1 |
| Wilson, GM | 1 |
| Guan, Y | 1 |
| Wang, CY | 1 |
| Wang, X | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Employment Retention Issues for Patient With Pseudoxanthoma Elasticum[NCT05246189] | 99 participants (Actual) | Observational | 2022-04-07 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for diphosphoric acid and Vascular Calcification
| Article | Year |
|---|---|
Vascular Calcification: Key Roles of Phosphate and Pyrophosphate.
Topics: Diphosphates; Humans; Phosphates; Vascular Calcification | 2021 |
Inorganic Pyrophosphate Deficiency Syndromes and Potential Treatments for Pathologic Tissue Calcification.
Topics: Ankylosis; Calcinosis; Choristoma; Diphosphates; Humans; Pseudoxanthoma Elasticum; Syndrome; Vascula | 2022 |
Role of the extracellular ATP/pyrophosphate metabolism cycle in vascular calcification.
Topics: Adenosine Triphosphate; Diphosphates; Homeostasis; Humans; Vascular Calcification | 2023 |
Pseudoxanthoma Elasticum, Kidney Stones and Pyrophosphate: From a Rare Disease to Urolithiasis and Vascular Calcifications.
Topics: 5'-Nucleotidase; Diphosphates; GPI-Linked Proteins; Humans; Kidney Calculi; Multidrug Resistance-Ass | 2019 |
Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management.
Topics: Adenosine Monophosphate; Bone Density Conservation Agents; Calcinosis; Cardiovascular Agents; Chelat | 2020 |
Molecular Genetics and Modifier Genes in Pseudoxanthoma Elasticum, a Heritable Multisystem Ectopic Mineralization Disorder.
Topics: Animals; Diphosphates; Genetic Association Studies; Humans; Mice; Multidrug Resistance-Associated Pr | 2021 |
ABCC6, Pyrophosphate and Ectopic Calcification: Therapeutic Solutions.
Topics: 5'-Nucleotidase; Animals; ATP-Binding Cassette Transporters; Calcification, Physiologic; Calcinosis; | 2021 |
Insights into Pathomechanisms and Treatment Development in Heritable Ectopic Mineralization Disorders: Summary of the PXE International Biennial Research Symposium-2016.
Topics: 5'-Nucleotidase; Alkaline Phosphatase; Animals; Biopsy, Needle; Clinical Trials as Topic; Congresses | 2017 |
Vascular ossification: Pathology, mechanisms, and clinical implications.
Topics: 5'-Nucleotidase; alpha-2-HS-Glycoprotein; Animals; Diphosphates; GPI-Linked Proteins; Humans; Ossifi | 2018 |
Pyrophosphate deficiency in vascular calcification.
Topics: Animals; Blood Vessels; Calcium; Diphosphates; Down-Regulation; Genetic Predisposition to Disease; H | 2018 |
Pseudoxanthoma Elasticum as a Paradigm of Heritable Ectopic Mineralization Disorders: Pathomechanisms and Treatment Development.
Topics: 5'-Nucleotidase; Diphosphates; Diphosphonates; GPI-Linked Proteins; Humans; Multidrug Resistance-Ass | 2019 |
Modulators of networks: molecular targets of arterial calcification identified in man and mice.
Topics: Adenosine Triphosphate; Animals; Diphosphates; Humans; Mice; Receptors, Calcitriol; Signal Transduct | 2014 |
The role of carbonic anhydrase in the pathogenesis of vascular calcification in humans.
Topics: Animals; Blood Vessels; Calcium-Binding Proteins; Carbon-Carbon Ligases; Carbonic Anhydrases; Diphos | 2015 |
Research Progress in Pseudoxanthoma Elasticum and Related Ectopic Mineralization Disorders.
Topics: 5'-Nucleotidase; Animals; Biomedical Research; Diphosphates; Forecasting; Genetic Predisposition to | 2016 |
1 trial available for diphosphoric acid and Vascular Calcification
| Article | Year |
|---|---|
Acute and 3-month effects of calcium carbonate on the calcification propensity of serum and regulators of vascular calcification: secondary analysis of a randomized controlled trial.
Topics: Aged; alpha-2-HS-Glycoprotein; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbon | 2016 |
18 other studies available for diphosphoric acid and Vascular Calcification
| Article | Year |
|---|---|
Oral supplementation of inorganic pyrophosphate in pseudoxanthoma elasticum.
Topics: Animals; Dietary Supplements; Diphosphates; Humans; Mice; Mutation; Phosphoric Diester Hydrolases; P | 2022 |
Weighing the Evidence for the Roles of Plasma Versus Local Pyrophosphate in Ectopic Calcification Disorders.
Topics: Bone and Bones; Calcium, Dietary; Diphosphates; Humans; Minerals; Vascular Calcification | 2023 |
Pyrophosphate therapy prevents trauma-induced calcification in the mouse model of neurogenic heterotopic ossification.
Topics: Adrenergic Antagonists; Animals; Brain Injuries, Traumatic; Cardiotoxins; Diphosphates; Disease Mode | 2020 |
Hydrolysis of Extracellular ATP by Vascular Smooth Muscle Cells Transdifferentiated into Chondrocytes Generates P
Topics: Adenosine Triphosphate; Alkaline Phosphatase; Animals; Aorta; Ascorbic Acid; Atherosclerosis; Cell T | 2021 |
Novel phosphate-activated macrophages prevent ectopic calcification by increasing extracellular ATP and pyrophosphate.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Calcium; Diphosphates; Flow Cytometry; Macrophages; M | 2017 |
Synthesis of Extracellular Pyrophosphate Increases in Vascular Smooth Muscle Cells During Phosphate-Induced Calcification.
Topics: Alkaline Phosphatase; Animals; Antigens, CD; Aorta; Apyrase; Bone Morphogenetic Protein 2; Cell Prol | 2018 |
ENPP1 enzyme replacement therapy improves blood pressure and cardiovascular function in a mouse model of generalized arterial calcification of infancy.
Topics: Animals; Blood Pressure; Cardiovascular System; Diphosphates; Disease Models, Animal; Enzyme Replace | 2018 |
Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment.
Topics: Adenosine Triphosphate; Alkaline Phosphatase; Animals; Aorta; Cells, Cultured; Diphosphates; Disease | 2013 |
Vascular calcification: an age-old problem of old age.
Topics: Animals; Diphosphates; Male; Progeria; Vascular Calcification | 2013 |
Mutant Enpp1asj mice as a model for generalized arterial calcification of infancy.
Topics: Animals; Base Sequence; Calcification, Physiologic; Calcium; Diet; Diphosphates; Disease Models, Ani | 2013 |
Effects of pyrophosphate delivery in a peritoneal dialysis solution on bone tissue of apolipoprotein-E knockout mice with chronic kidney disease.
Topics: Animals; Apolipoproteins E; Bone Density; Dialysis Solutions; Diphosphates; Female; Femur; Mice; Mic | 2014 |
Vascular calcification is dependent on plasma levels of pyrophosphate.
Topics: Animals; Aorta; Aortic Diseases; Calcium; Diphosphates; Disease Models, Animal; Disease Progression; | 2014 |
Smad3 plays an inhibitory role in phosphate-induced vascular smooth muscle cell calcification.
Topics: Animals; Blotting, Western; Chromatin Immunoprecipitation; Diphosphates; Male; Mice; Mice, Knockout; | 2014 |
Calpain-1 Mediated Disorder of Pyrophosphate Metabolism Contributes to Vascular Calcification Induced by oxLDL.
Topics: Animals; Aorta; Calcium; Calpain; Cell Line; Diphosphates; Glycoproteins; Hypercholesterolemia; Lipo | 2015 |
Phosphate, pyrophosphate, and vascular calcification: a question of balance.
Topics: Computed Tomography Angiography; Coronary Angiography; Diphosphates; Humans; Phosphates; Vascular Ca | 2017 |
Can Intestinal Phosphate Binding or Inhibition of Hydroxyapatite Growth in the Vascular Wall Halt the Progression of Established Aortic Calcification in Chronic Kidney Disease?
Topics: Animals; Aorta; Chelating Agents; Diphosphates; Durapatite; Male; Rats; Rats, Wistar; Renal Insuffic | 2016 |
Calcium phosphate deposition with normal phosphate concentration. -Role of pyrophosphate-.
Topics: Animals; Calcium; Cells, Cultured; Diphosphates; Durapatite; Models, Biological; Muscle, Smooth, Vas | 2011 |
Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression.
Topics: Animals; Atherosclerosis; Diphosphates; Disease Models, Animal; Disease Progression; Down-Regulation | 2012 |